Background: Antegrade femoral access is fraught by technical challenges and steeper learning curve, in comparison with retrograde contralateral femoral access. We appraised learning curve, complications, and technical aspects inherent in the adoption of antegrade approach.
Methods: Consecutive cases in which antegrade access was attempted by a cardiologist experienced in retrograde access, but inexperienced in antegrade, under supervision of an operator with anterograde expertise, were collected. The primary end-point was the occurrence of antegrade access failure or local complications. Major complications were defined as those life-threatening, requiring transfusion, percutaneous, or surgical repair.
Results: Anterograde access was attempted in 120 patients. The primary end-point occurred in 14 (11.6%) cases, but according to the learning curve, in 12 (20%) for first 60 cases vs 2 (3.3%) for the last 60 cases (P = 0.008). Access failure in the hands of the in-training operator was similarly found in all cases but one during the first 60 cases. No major complications occurred, while minor complications were found in 9 (7.5%) patients, again with all but two of them occurring in the first 60 cases. These included peri-adventitial extravasation in 8 patients (6.7%), and perforation of a small branch in one (0.8%); all these complications were conservatively and successfully managed. Obesity was the only significant predictor of access failure/complication (P = 0.004).
Conclusions: This work, the first to report on the learning curve of the antegrade approach, supports the feasibility and safety of this access site even for an in-training operator, if supervised. A minimum caseload of 60 procedures is likely needed to master this technique.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/ccd.20930 | DOI Listing |
JACC Asia
January 2025
Department of Frontier Cardiovascular Science, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Background: Heart failure should be diagnosed as early as possible. Although deep learning models can predict one or more echocardiographic findings from electrocardiograms (ECGs), such analyses are not comprehensive.
Objectives: This study aimed to develop a deep learning model for comprehensive prediction of echocardiographic findings from ECGs.
BMJ Oncol
July 2024
National Institute for Data Science in Health and Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Objective: To develop and validate machine-learning models that predict the risk of pan-cancer incidence using demographic, questionnaire and routine health check-up data in a large Asian population.
Methods And Analysis: This study is a prospective cohort study including 433 549 participants from the prospective MJ cohort including a male cohort (n=208 599) and a female cohort (n=224 950).
Results: During an 8-year median follow-up, 5143 cancers occurred in males and 4764 in females.
BMJ Oncol
February 2024
Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen & Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Objective: Fast progression (FP) represents a desperate situation for advanced non-small cell lung cancer (NSCLC) patients undergoing immune checkpoint inhibitor therapy. We aimed to develop a predictive framework based on machine learning (ML) methods to identify FP in advanced NSCLC patients using blood test biomarkers.
Methods And Analysis: We extracted data of 1546 atezolizumab-treated patients from four multicentre clinical trials.
Front Digit Health
January 2025
Department of Demography & Social Statistics, Federal University, Birnin-Kebbi, Kebbi State, Nigeria.
Background: Fertility preferences refer to the number of children an individual would like to have, regardless of any obstacles that may stand in the way of fulfilling their aspirations. Despite the creation and application of numerous interventions, the overall fertility rate in West African nations, particularly Nigeria, is still high at 5.3% according to 2018 Nigeria Demographic and Health Survey data.
View Article and Find Full Text PDFBMJ Oncol
January 2025
Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center, Jerry H Hodge School of Pharmacy, Abilene, Texas, USA.
In 2025, it will be 30 years since the initial clinical approval of pegylated liposomal doxorubicin (PLD) by the Food and Drug Administration. PLD predated the field of nanomedicine and became a model nanomedicine setting key pharmacological principles (prolonged circulation, slow drug release and the enhanced permeability and retention (EPR) effect) for clinical application of other nano-drugs in cancer therapy. The impressive reduction of cardiotoxicity conferred by PLD is the most valuable clinical asset.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!